EGFR and neoplasm: In addition to RAS mutation, other resistant mechanism of mCRC to anti-EGFR antibodies includes the aberrant VEGF signaling 19, i.e., a higher tumor VEGF expression is associated with worse overall survival in mCRC patients treated with anti-EGFR antibodies 20.